Activating mutations in Kristen Rat Sarcoma viral oncogene (KRAS) represents the most prevalent genetic aberrations in NSCLC patients, manifesting at a frequency around 25–30% of cases [41,42]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.